Vernalis cures its Frova migraine

Vernalis plc was cash strapped after buying back North American marketing rights for its Frova frovatriptan migraine drug from Elan Corp. plc in May. But a new deal selling those rights to Endo Pharmaceutical Holdings Inc. spares Vernalis the need to return to the market to pay off its debt to ELN. In addition, the new terms look more advantageous to Vernalis.

The original deal was unwound so ELN could focus on its expected launches of Antegren natalizumab to treat multiple sclerosis (MS) and Crohn's disease and of Prialt ziconotide to treat severe chronic pain...